DNA helicase Inhibitors
2 drugsAbout DNA helicase
DNA helicases are essential enzymes that unwind double-stranded DNA, enabling replication, repair, and transcription. They act as molecular 'unzippers,' separating DNA strands for these critical cellular processes. Their fundamental role makes them attractive targets for drug development, especially in oncology.
Disrupting helicase function can halt DNA replication and induce cell death, making them valuable in cancer therapy. Currently, there is no genetic evidence linking DNA helicases to specific diseases, highlighting an area for future investigation.
Two FDA-approved drugs target DNA helicases: ELLENCE (Pfizer) and EPIRUBICIN HYDROCHLORIDE (EPIC PHARMA LLC), both small molecules. These drugs are used in oncology and other therapeutic areas, with approvals spanning from 1999 to 2006.
Top DNA helicase Drugs
The competitive landscape includes two companies with approved drugs: EPIC PHARMA LLC and Pfizer.
Low market concentration suggests relatively low barriers to entry, but also potential for intense competition.
DNA helicase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DNA helicase, using small molecule modality.
Explore opportunities for novel modalities like antibodies or PROTACs to differentiate from existing small molecule drugs.
DNA helicase Clinical Trials 118 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNA helicase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 9 | 1 | 3 | 90% |
| Phase 2 | 72 | 28 | 13 | 29 | 68% |
| Phase 3 | 29 | 15 | 4 | 10 | 79% |
| Phase 4 | 4 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DNA helicase Drug Approval Timeline (1999 - 1999)
The first drug targeting DNA helicases was approved in 1999, with the most recent approval in 2006.
The limited approval span suggests potential saturation or challenges in developing new drugs targeting this mechanism.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 70 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNA helicase. A trial counts if an approved drug acting on DNA helicase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.